Product image of Irbesartan Comp Hexal (Hydrochlorothiazide, Irbesartan) supplied by GNH India

Irbesartan Comp Hexal

Active Ingredient:
Hydrochlorothiazide, Irbesartan
Origin:
EU

Irbesartan Comp Hexal (Hydrochlorothiazide, Irbesartan)

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbesartan Comp Hexal, are an angiotensin II receptor blocker and a thiazide diuretic presented as tablets for oral use. They treat hypertension in adult patients by lowering blood pressure and reducing fluid retention.
GNH India supplies Irbesartan Comp Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Irbesartan Comp Hexal acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control high blood pressure.

  • Hypertension: lowers systolic and diastolic pressure in adults.
  • Essential hypertension uncontrolled by monotherapy: provides additional blood‑pressure reduction when a single agent is insufficient.
  • Hypertension with fluid retention: combines antihypertensive and diuretic effects to improve overall control.

How It Works

  • Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary excretion of sodium and water. The combined actions reduce vascular resistance and plasma volume, resulting in lowered arterial pressure.

Side Effects

Common Side Effects

  • Dizziness: sensation of light‑headedness, especially after standing.
  • Headache: mild to moderate pain in the head region.
  • Fatigue: feeling unusually tired or weak.
  • Increased urination: more frequent need to void.
  • Electrolyte imbalance: changes in potassium or sodium levels.
  • Mild gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

  • Severe hypotension: dangerously low blood pressure.
  • Hyperkalemia: elevated potassium that can affect heart rhythm.
  • Acute kidney injury: sudden decline in renal function.
  • Allergic reactions: rash, itching, or swelling.
  • Pancreatitis: inflammation of the pancreas.
  • Blood dyscrasias: abnormal blood cell counts.

Precautions & Warnings

Before initiating therapy, consider the following precautions.

  • Blood pressure monitoring: check regularly to ensure adequate control.
  • Electrolyte assessment: evaluate potassium and sodium levels, especially with diuretic use.
  • Renal function: assess kidney function before and during treatment.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Pregnancy and lactation: safety not established; avoid unless clearly needed.
  • Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Irbesartan Comp Hexal may interact with several medicines; review patient medication lists.

Major Interactions (Avoid)

  • Aliskiren in diabetic patients: risk of severe hypotension and renal impairment.
  • Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
  • NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and affect kidney function.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: additive blood‑pressure lowering, monitor for hypotension.
  • Lithium: increased lithium levels, watch for toxicity.
  • Other antihypertensives: may require dose adjustments.
  • Antidiabetic agents: blood‑glucose may improve, monitor for hypoglycemia.
  • CYP3A4 inhibitors: may increase irbesartan exposure, observe for adverse effects.

Frequently Asked Questions

Irbesartan Comp Hexal is prescribed to lower high blood pressure in adult patients. It combines an angiotensin II receptor blocker with a thiazide diuretic to provide both vasodilation and increased urinary fluid loss, helping achieve better blood‑pressure control.

Irbesartan blocks AT1 receptors, preventing angiotensin II from causing blood‑vessel constriction and aldosterone release. Hydrochlorothiazide, the accompanying diuretic, reduces sodium and chloride reabsorption in the kidney’s distal tubule, promoting water excretion. Together they lower vascular resistance and blood volume.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health. The prescriber will select the appropriate tablet strength and frequency for each individual.

Safety in pregnancy and lactation has not been established for this combination product. It should generally be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with single‑agent ARBs or thiazide diuretics, this fixed‑dose combination offers the convenience of two mechanisms in one tablet, often achieving greater blood‑pressure reduction than either component alone. It may reduce pill burden versus separate prescriptions, but individual patient factors dictate the best therapy.

Store the tablets at temperatures below 25 °C in their original packaging, protecting them from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush, chew, or split unless specifically instructed.

Serious risks include severe hypotension, hyperkalemia (especially when combined with potassium‑sparing agents), acute kidney injury, and rare allergic reactions such as angioedema. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

The combination should be avoided in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any excipients, as well as in individuals with severe renal impairment, anuria, or those taking aliskiren in combination with diabetes. Clinicians must evaluate each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hydrochlorothiazide, Irbesartan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT